THOUSAND OAKS, Calif., Jan. 29, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key results include:
For the fourth quarter, total revenues increased 7 percent to $6.2 billion.
Product sales grew 8 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth.
For the full year, total revenues increased 4 percent to $23.7 billion, with 3 percent product sales growth.
GAAP earnings per share (EPS) increased to $3.01 in the…